Evidence map›Paper›PMID 42286635›Full record

ArticleRespiratory research2026

HLA-DR

Tsukie Kin Tsukuda, Minoru Fujimoto, Hiroshi Ohnishi, Kousuke Ooyama, Yu Nakatani, Takehiko Ito, Junki Terada, Yuichi Baba, Toru Kubo, Akihito Yokoyama and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tsukie Kin TsukudaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan. tsukiet@kochi-u.ac.jp.
Minoru FujimotoCenter for the Intractable Immune Disease, Kochi Medical School, Kochi University, Nankoku, Japan.
Hiroshi OhnishiDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.
Kousuke OoyamaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.
Yu NakataniDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.
Takehiko ItoDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.
Junki TeradaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.
Yuichi BabaDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Nankoku, Japan.
Toru KuboDepartment of Cardiology and Geriatrics, Kochi Medical School, Kochi University, Nankoku, Japan.
Akihito YokoyamaDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.
Tetsuji NakaCenter for the Intractable Immune Disease, Kochi Medical School, Kochi University, Nankoku, Japan.
Toshiyuki KozukiDepartment of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, 783-8505, Kochi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcoidosis is a systemic granulomatous disease caused by sustained activation of CD4

methodsWe compared and evaluated the proportions and activation states of Th17.1 cells and regulatory T cells in peripheral blood (n = 34) and bronchoalveolar lavage fluid (n = 22) from patients with pulmonary sarcoidosis, and from patients with connective tissue disease-associated interstitial lung disease (n = 36, 34). We also conducted a longitudinal investigation of changes before and after corticosteroid treatment and associations with disease progression.

resultsThe proportion of activated Th17.1 cells was higher in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis than from patients with connective tissue disease-associated interstitial lung disease. However, this proportion decreased with corticosteroid administration and was associated with disease progression. The proportion of regulatory T cells was significantly lower in the lungs of sarcoidosis patients compared to those with connective tissue disease-associated interstitial lung disease.

conclusionAmong patients with corticosteroid-responsive pulmonary sarcoidosis, activation of Th17.1 cells reflects disease activity.

Indexed as

Adrenal Cortex HormonesHLA-DR AntigensLymphocyte ActivationSarcoidosis, PulmonaryTh17 CellsAdultAgedBronchoalveolar Lavage FluidFemaleHumansLongitudinal StudiesMaleMiddle AgedT-Lymphocytes, RegulatoryAdrenal Cortex HormonesHLA-DR AntigensActivated CD4+ T cellConnective tissue disease-associated interstitial lung diseaseCorticosteroid responsivenessPulmonary sarcoidosisRegulatory T cellTh17.1 cell

Identifiers

PMID42286635
PMCPMC13505099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.